Loading patent…
AssigneesOmeros Corporation, University of Leicester
InventorsHans-Wilhelm Schwaeble, Clark E. Tedford, James B. Parent, Thomas Dudler, Gregory A. Demopulos
Estimating the term…
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
A method of inhibiting adverse effects of transplantation in a subject that has undergone, is undergoing, or will undergo a liver transplant procedure comprising administering to the subject, or pretreating the liver to be transplanted with, a composition comprising a monoclonal MASP-2 inhibitory antibody, or antigen-binding fragment thereof, that specifically binds to a portion of SEQ ID NO:6 and inhibits MASP 2 dependent complement activation.
Dependencies are inferred from the claim text.